Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials - PubMed (original) (raw)
Review
. 2018 Mar;20(3):620-628.
doi: 10.1111/dom.13124. Epub 2017 Oct 26.
Affiliations
- PMID: 28950419
- PMCID: PMC5836959
- DOI: 10.1111/dom.13124
Review
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
Serge Jabbour et al. Diabetes Obes Metab. 2018 Mar.
Abstract
Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM).
Methods: Data were pooled from 13 placebo-controlled trials of up to 24 weeks' duration (dapagliflozin, n = 2360; placebo, n = 2295). Larger placebo-/comparator-controlled pools of 21 (≤208 weeks; dapagliflozin, n = 5936; control, n = 3403) and 30 trials (≥12 weeks; dapagliflozin, n = 9195; control, n = 4629) assessed the rare adverse events (AEs) of diabetic ketoacidosis (DKA) and lower limb amputation, respectively.
Results: Over 24 weeks, the overall incidence of AEs and serious AEs (SAEs) was similar for dapagliflozin and placebo: 60.0% vs 55.7% and 5.1% vs 5.4%, respectively. Rates of hypoglycaemia, volume depletion AEs, urinary tract infections (UTIs) and fractures were balanced between the groups. Genital infections were more frequent with dapagliflozin (5.5%) vs placebo (0.6%) and renal function AEs occurred in 3.2% vs 1.8% of patients (the most common renal AE was decreased creatinine clearance: 1.1% vs 0.7%). In the 21-study pool, 1 SAE of DKA and 3 AEs of ketonuria/metabolic acidosis occurred with dapagliflozin vs none with control; estimated combined incidence for these events was 0.03% (95% confidence interval 0.010-0.089). In the 30-study pool, lower limb amputation occurred in 8 (0.1%) and 7 (0.2%) patients receiving dapagliflozin and control, respectively.
Conclusion: The overall incidence rates of AEs and SAEs were similar in the dapagliflozin and placebo/control groups, including the incidence of hypoglycaemia, volume depletion, fractures, UTIs, amputations and DKA. Genital infections were more frequent with dapagliflozin than placebo.
Keywords: SGLT2 inhibitor; antidiabetic drug; dapagliflozin; type 2 diabetes.
© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Conflict of interest statement
S. J. is a consultant for AstraZeneca, Janssen and Eli Lilly. J. S. has attended advisory boards and/or speaker's bureaus for Takeda, Bayer, Novartis, Merck Sharp & Dohme, Amgen, AstraZeneca, Bristol‐Myers Squibb, Novo Nordisk, Sanofi, Berlin‐Chemie, Eli Lilly, Boehringer Ingelheim, Merck, Roche, Ipsen, Pfizer, Janssen and LifeScan, and has received project‐specific research support from AstraZeneca, Takeda, Novartis, Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Novo Nordisk, Sanofi, Ipsen, Pfizer, Janssen, Servier, Eli Lilly, Apitope, Intarcia and Roche. A.S. has attended advisory boards and/or speaker's bureaus for AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim and Janssen, and has received research support from Novo Nordisk. C. J. B. received grants and personal fees from AstraZeneca, Bristol‐Myers Squibb, Sanofi and personal fees from Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme, Novo Nordisk, Elcelyx and Poxel, outside of the submitted work. C. K. and A. M. L. are employees and stockholders of AstraZeneca.
Figures
Figure 1
Values for eGFR over time (13‐study pool). eGFR was calculated using the Modification in Diet and Renal Disease (MDRD) formula. BL, baseline; s.e., standard error. Patients at baseline denote the number of treated patients with non‐missing baseline values
Similar articles
- Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S. Fioretto P, et al. Drugs Aging. 2016 Jul;33(7):511-22. doi: 10.1007/s40266-016-0382-1. Drugs Aging. 2016. PMID: 27357173 Free PMC article. - Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29. Diabetes Obes Metab. 2014. PMID: 23911013 Clinical Trial. - Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Ptaszynska A, et al. Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4. Drug Saf. 2014. PMID: 25096959 - Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
McGill JB, Subramanian S. McGill JB, et al. Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-S52. doi: 10.1016/j.amjcard.2019.10.029. Am J Cardiol. 2019. PMID: 31741440 Review. - Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Zaccardi F, et al. Diabetes Obes Metab. 2016 Aug;18(8):783-94. doi: 10.1111/dom.12670. Epub 2016 May 13. Diabetes Obes Metab. 2016. PMID: 27059700 Review.
Cited by
- Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.
Chang RC, Miller RL, Kwon KW, Huang JC. Chang RC, et al. Adv Ther. 2024 Aug;41(8):3247-3263. doi: 10.1007/s12325-024-02919-5. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958842 Free PMC article. - Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M, Guo J, Smith SM, Dietrich EA, Winchester DE, Park H. Riaz M, et al. Am J Cardiovasc Drugs. 2024 May;24(3):455-464. doi: 10.1007/s40256-024-00648-2. Epub 2024 Apr 30. Am J Cardiovasc Drugs. 2024. PMID: 38691312 - Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction.
Alfieri M, Bruscoli F, Di Vito L, Di Giusto F, Scalone G, Marchese P, Delfino D, Silenzi S, Martoni M, Guerra F, Grossi P. Alfieri M, et al. J Cardiovasc Dev Dis. 2024 Apr 19;11(4):125. doi: 10.3390/jcdd11040125. J Cardiovasc Dev Dis. 2024. PMID: 38667743 Free PMC article. Review. - Sample size determination for time-to-event endpoints in randomized selection trials with generalized exponential distribution.
Akbar MH, Ali S, Shah I, Alqifari HN. Akbar MH, et al. Heliyon. 2024 Feb 28;10(5):e27013. doi: 10.1016/j.heliyon.2024.e27013. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38455536 Free PMC article. - Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
Li CX, Liu TT, Zhang Q, Xie Q, Geng XH, Man CX, Li JY, Mao XY, Qiao Y, Liu H. Li CX, et al. Front Pharmacol. 2023 Oct 13;14:1275060. doi: 10.3389/fphar.2023.1275060. eCollection 2023. Front Pharmacol. 2023. PMID: 37905204 Free PMC article.
References
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. - PubMed
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. - PubMed
- Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–519. - PubMed
- Scheen AJ. Pharmacodynamics, efficacy and safety of sodium‐glucose co‐transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical